5.57 USD
+0.09 (+1.64%)
Overall ICCC gets a fundamental rating of 4 out of 10. We evaluated ICCC against 531 industry peers in the Biotechnology industry. ICCC has only an average score on both its financial health and profitability. ICCC has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ICCC was profitable.
In the past year ICCC had a positive cash flow from operations.
ICCC had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ICCC reported negative operating cash flow in multiple years.
1.2 Ratios
ICCC has a Return On Assets of 5.08%. This is amongst the best in the industry. ICCC outperforms 91.34% of its industry peers.
The Return On Equity of ICCC (7.80%) is better than 91.71% of its industry peers.
The Return On Invested Capital of ICCC (4.41%) is better than 90.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.08% | ||
| ROE | 7.8% | ||
| ROIC | 4.41% |
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ICCC's Profit Margin of 8.37% is amongst the best of the industry. ICCC outperforms 90.40% of its industry peers.
With an excellent Operating Margin value of 8.39%, ICCC belongs to the best of the industry, outperforming 90.77% of the companies in the same industry.
With a decent Gross Margin value of 40.93%, ICCC is doing good in the industry, outperforming 73.82% of the companies in the same industry.
ICCC's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.39% | ||
| PM (TTM) | 8.37% | ||
| GM | 40.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
2. Health
2.1 Basic Checks
ICCC has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ICCC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ICCC has more shares outstanding
Compared to 1 year ago, ICCC has an improved debt to assets ratio.
2.2 Solvency
ICCC has an Altman-Z score of 2.60. This is not the best score and indicates that ICCC is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of ICCC (2.60) is better than 66.67% of its industry peers.
The Debt to FCF ratio of ICCC is 13.27, which is on the high side as it means it would take ICCC, 13.27 years of fcf income to pay off all of its debts.
ICCC's Debt to FCF ratio of 13.27 is amongst the best of the industry. ICCC outperforms 89.83% of its industry peers.
ICCC has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.27, ICCC is not doing good in the industry: 69.30% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 13.27 | ||
| Altman-Z | 2.6 |
ROIC/WACC0.53
WACC8.32%
2.3 Liquidity
ICCC has a Current Ratio of 4.21. This indicates that ICCC is financially healthy and has no problem in meeting its short term obligations.
ICCC has a Current ratio of 4.21. This is comparable to the rest of the industry: ICCC outperforms 49.72% of its industry peers.
ICCC has a Quick Ratio of 1.76. This is a normal value and indicates that ICCC is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.76, ICCC is not doing good in the industry: 78.91% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.21 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
ICCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.00%, which is quite impressive.
ICCC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.49%.
The Revenue has been growing by 14.07% on average over the past years. This is quite good.
EPS 1Y (TTM)152%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)16.49%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%-8.32%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.42, the valuation of ICCC can be described as rather expensive.
Based on the Price/Earnings ratio, ICCC is valued cheaply inside the industry as 93.97% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.28, ICCC is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.42 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ICCC indicates a rather cheap valuation: ICCC is cheaper than 96.23% of the companies listed in the same industry.
92.09% of the companies in the same industry are more expensive than ICCC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 70.46 | ||
| EV/EBITDA | 10.98 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ICCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ICCC (12/9/2025, 8:00:02 PM)
5.57
+0.09 (+1.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners19.56%
Inst Owner Change-3.09%
Ins Owners26.35%
Ins Owner Change0.8%
Market Cap50.41M
Revenue(TTM)27.77M
Net Income(TTM)2.32M
Analysts82.86
Price TargetN/A
Short Float %0.09%
Short Ratio0.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.42 | ||
| Fwd PE | N/A | ||
| P/S | 1.82 | ||
| P/FCF | 70.46 | ||
| P/OCF | 25.33 | ||
| P/B | 1.69 | ||
| P/tB | 1.7 | ||
| EV/EBITDA | 10.98 |
EPS(TTM)0.26
EY4.67%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY1.42%
OCF(TTM)0.22
OCFY3.95%
SpS3.07
BVpS3.29
TBVpS3.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.08% | ||
| ROE | 7.8% | ||
| ROCE | 5.58% | ||
| ROIC | 4.41% | ||
| ROICexc | 4.86% | ||
| ROICexgc | 4.87% | ||
| OM | 8.39% | ||
| PM (TTM) | 8.37% | ||
| GM | 40.93% | ||
| FCFM | 2.58% |
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 13.27 | ||
| Debt/EBITDA | 1.57 | ||
| Cap/Depr | 47.25% | ||
| Cap/Sales | 4.59% | ||
| Interest Coverage | 5.01 | ||
| Cash Conversion | 39.59% | ||
| Profit Quality | 30.79% | ||
| Current Ratio | 4.21 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z | 2.6 |
F-Score7
WACC8.32%
ROIC/WACC0.53
Cap/Depr(3y)82.27%
Cap/Depr(5y)105.22%
Cap/Sales(3y)11.34%
Cap/Sales(5y)14.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.49%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%-8.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y171.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y108.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y137.97%
OCF growth 3Y-27.78%
OCF growth 5Y9.25%
IMMUCELL CORP / ICCC FAQ
Can you provide the ChartMill fundamental rating for IMMUCELL CORP?
ChartMill assigns a fundamental rating of 4 / 10 to ICCC.
Can you provide the valuation status for IMMUCELL CORP?
ChartMill assigns a valuation rating of 4 / 10 to IMMUCELL CORP (ICCC). This can be considered as Fairly Valued.
Can you provide the profitability details for IMMUCELL CORP?
IMMUCELL CORP (ICCC) has a profitability rating of 5 / 10.
What is the valuation of IMMUCELL CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IMMUCELL CORP (ICCC) is 21.42 and the Price/Book (PB) ratio is 1.69.
Can you provide the financial health for ICCC stock?
The financial health rating of IMMUCELL CORP (ICCC) is 5 / 10.